Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Sunil Nagpal

Hematology Oncology | Hematology | Oncology
Bronson Healthcare
Bronson Methodist Hospital
805 John St, 
Kalamazoo, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Bronson Healthcare
Bronson Methodist Hospital
805 John St, 
Kalamazoo, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sunil Nagpal is a Hematologist Oncology specialist and a Hematologist in Kalamazoo, Michigan. Dr. Nagpal is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Tissue Biopsy. Dr. Nagpal is currently accepting new patients.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Bronson South Haven Hospital
Bronson Battle Creek Hospital
Bronson Lakeview Hospital
Bronson Methodist Hospital
Borgess Medical Center
Languages Spoken
English
Hindi
Punjabi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

BRONSON METHODIST HOSPITAL
805 John St, Kalamazoo, MI 49001
Call: 269-286-7170

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


15 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustin, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Enrollment Status: Unknown
Publish Date: December 29, 2021
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
Enrollment Status: Completed
Publish Date: August 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 14 Less Clinical Trials

29 Total Publications

Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset.
Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset.
Journal: Science advances
Published: September 25, 2024
View All 29 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rashid Z. Khan
Oncology | Hematology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rashid Z. Khan
Oncology | Hematology | Hematology Oncology

Michiana Hematology-Oncology P C

5340 Holy Cross Pkwy, 
Mishawaka, IN 
 (49.9 miles away)
574-237-1328
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Rashid Khan is an Oncologist and a Hematologist in Mishawaka, Indiana. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Multiple Myeloma, Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Khan is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Dustin A. Bivins
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Dustin A. Bivins
Hematology Oncology | Hematology | Oncology

Bronson Methodist Hospital

805 John St, 
Kalamazoo, MI 
 (0.1 miles away)
269-286-7170
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dustin Bivins is a Hematologist Oncology specialist and a Hematologist in Kalamazoo, Michigan. Dr. Bivins is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, and Atypical Teratoid Rhabdoid Tumor (ATRT). Dr. Bivins is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sapna Patel
Oncology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sapna Patel
Oncology | Hematology Oncology

Bronson Battle Creek Hospital

300 N Ave, 
Battle Creek, MI 
 (20.8 miles away)
Languages Spoken:
English
See accepted insurances

Sapna Patel is an Oncologist and a Hematologist Oncology provider in Battle Creek, Michigan. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nagpal's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Nagpal is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Nagpal is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Chronic Myelogenous Leukemia (CML)
      Dr. Nagpal is
      Distinguished
      . Learn about Chronic Myelogenous Leukemia (CML).
      See more Chronic Myelogenous Leukemia (CML) experts
    • Familial Pancreatic Cancer
      Dr. Nagpal is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Inflammatory Breast Cancer
      Dr. Nagpal is
      Distinguished
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Intraductal Papilloma
      Dr. Nagpal is
      Distinguished
      . Learn about Intraductal Papilloma.
      See more Intraductal Papilloma experts
    View All 12 Distinguished Conditions
    • Advanced
    • Acute Mountain Sickness
      Dr. Nagpal is
      Advanced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Adult Immune Thrombocytopenia
      Dr. Nagpal is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Agranulocytosis
      Dr. Nagpal is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Nagpal is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Breast Cancer in Men
      Dr. Nagpal is
      Advanced
      . Learn about Breast Cancer in Men.
      See more Breast Cancer in Men experts
    • Childhood Acute Myeloid Leukemia
      Dr. Nagpal is
      Advanced
      . Learn about Childhood Acute Myeloid Leukemia.
      See more Childhood Acute Myeloid Leukemia experts
    View All 20 Advanced Conditions
    • Experienced
    • Acute Hepatic Porphyria (AHP)
      Dr. Nagpal is
      Experienced
      . Learn about Acute Hepatic Porphyria (AHP).
      See more Acute Hepatic Porphyria (AHP) experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Nagpal is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Nagpal is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Nagpal is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Acute Myelomonocytic Leukemia
      Dr. Nagpal is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Adult Soft Tissue Sarcoma
      Dr. Nagpal is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    View All 114 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved